AQS Insider Trading

Insider Ownership Percentage: 14.96%
Insider Buying (Last 12 Months): C$26,540.00
Insider Selling (Last 12 Months): C$0.00

Aequus Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Aequus Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aequus Pharmaceuticals Share Price & Price History

Current Price: C$0.03
Price Change: Price Decrease of -0.005 (-16.67%)
As of 03/31/2023 06:17 PM ET

This chart shows the closing price history over time for AQS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Aequus Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2022Doug JanzenDirectorBuy285,000C$0.04C$11,400.0012,553,800
11/20/2022Doug JanzenDirectorBuy115,000C$0.03C$3,450.0012,268,800
7/25/2022Marc LustigDirectorBuy64,000C$0.07C$4,480.00214,000
7/21/2022Marc LustigDirectorBuy4,000C$0.07C$280.00124,000
7/19/2022Doug JanzenDirectorBuy99,000C$0.07C$6,930.0012,052,800
9/1/2021Doug JanzenDirectorBuy500,000C$0.15C$72,500.0011,958,800
4/27/2021Doug JanzenDirectorBuy41,000C$0.19C$7,585.0010,999,800
1/15/2021Doug JanzenDirectorBuy130,000C$0.12C$15,600.009,326,300
12/31/2020Doug JanzenDirectorBuy100,000C$0.11C$11,000.009,196,300
12/29/2020Doug JanzenDirectorBuy100,000C$0.10C$10,100.009,096,300
10/30/2020Doug JanzenDirectorBuy21,500C$0.13C$2,687.508,646,300
10/20/2020Doug JanzenDirectorBuy150,000C$0.10C$15,150.008,624,800
See Full Table

SEC Filings (Institutional Ownership Changes) for Aequus Pharmaceuticals (CVE:AQS)

Aequus Pharmaceuticals logo
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Read More on Aequus Pharmaceuticals

Today's Range

Now: C$0.03
Low: C$0.03
High: C$0.03

50 Day Range

MA: C$0.04
Low: C$0.03
High: C$0.05

52 Week Range

Now: C$0.03
Low: C$0.02
High: C$0.08


45,673 shs

Average Volume

133,956 shs

Market Capitalization

C$3.32 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Aequus Pharmaceuticals?

Aequus Pharmaceuticals' top insider shareholders include:
  1. Doug Janzen (Director)
  2. Marc Lustig (Director)
Learn More about top insider investors at Aequus Pharmaceuticals.